Quantcast

Latest thyroid cancer Stories

2014-08-13 16:25:52

-- 2Q Revenue Increased 71%, Compared to Prior Year -- SOUTH SAN FRANCISCO, Calif., Aug. 13, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today reported financial results for the second quarter ended June 30, 2014, and provided an update on business progress. For the second quarter of 2014, revenue was $8.7 million, an increase of 71%, compared to $5.1 million for the second quarter of 2013. Revenue for the six months ended June 30, 2014 was $16.2 million, compared to $9.5 million for...

2014-08-13 16:25:43

Transaction Marks First Step Toward Creation of a Molecular Diagnostics Subsidiary to Aid in Patient Diagnosis and Management PARSIPPANY, N.J., Aug. 13, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, today announced that its Interpace Diagnostics subsidiary has entered the expanding cancer molecular diagnostics market with the acquisition of the miRInform(®) Thyroid and Pancreas cancer test assets from privately held Asuragen, Inc. This...

2014-08-10 23:01:12

The Firm is investigating Byetta lawsuits and other legal claims that allege incretin mimetics like Byetta, Januvia and Victoza caused patients to develop pancreatic cancer, pancreatitis or thyroid cancer. New York, New York (PRWEB) August 10, 2014 Byetta lawsuits (http://www.byettalawsuit.com) and legal claims involving other incretin mimetic Type 2 diabetes drugs, such as Januvia and Victoza, continue to move forward in a federal multidistrict litigation now underway in U.S. District...

2014-07-24 23:14:45

The routine use of a molecular testing panel developed at UPMC greatly increases the likelihood of performing the correct initial surgery for patients with thyroid nodules and cancer, report researchers from the University of Pittsburgh Cancer Institute (UPCI), partner with UPMC CancerCenter. Pittsburgh, Pennsylvania (PRWEB) July 24, 2014 The routine use of a molecular testing panel developed at UPMC greatly increases the likelihood of performing the correct initial surgery for patients...

2014-07-07 08:22:14

-- Nexavar is the only approved treatment for patients with RAI-refractory differentiated thyroid cancer -- Nexavar significantly extended progression-free survival in patients with RAI-refractory differentiated thyroid cancer compared to placebo in the Phase III DECISION trial TORONTO, July 7, 2014 /CNW/ - Bayer Inc. is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally...

2014-07-05 23:01:25

The Firm is evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer, due to their use of the Type 2 diabetes medication. New York, NY (PRWEB) July 05, 2014 Hundreds of Byetta lawsuits (http://www.byettalawsuit.com) and other incretin mimetic claims continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Southern District of California, Bernstein Liebhard LLP reports. According to...

2014-07-03 08:23:28

- Decisions to Cover Afirma for Use in Thyroid Cancer Diagnosis Bring Total Number of "Blues" Covered Lives to More than 10 Million - SOUTH SAN FRANCISCO, Calif., July 3, 2014 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the field of molecular cytology, today announced that two Blue Cross Blue Shield (BCBS)-affiliated organizations, Highmark Inc. and Horizon Blue Cross Blue Shield of New Jersey, have issued positive coverage policies for the company's...

2014-05-31 08:20:45

Phase III data for lenvatinib to be presented at ASCO WOODCLIFF LAKE, N.J., May 31, 2014 /PRNewswire/ -- Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC). Progression-free survival with lenvatinib was extended significantly compared to placebo (HR=0.21, [99% CI: 0.14-0.31]; p<0.0001). The median...

2014-05-19 23:04:54

Thyroid cancer increased from 14th to 5th most common cancer in women over last 20 years Fremont, California (PRWEB) May 19, 2014 The dramatic increase in the incidence of thyroid cancer worldwide over the past three decades likely relates to modifiable behavioral or environmental factors, as opposed to improved diagnostic capability, according to researchers at the Cancer Prevention Institute of California (CPIC) and their colleague at the Stanford University School of Medicine....

Scientists Seek Answers To Questions About Thyroid Cancer
2014-05-19 03:54:45

Jessica Nimon, NASA The multi-national efforts that go into research aboard the International Space Station show that working together can yield results with universal benefits. This is especially the case when talking about human health concerns such as cancer. Researchers make use of the microgravity environment aboard the space station to seek answers to questions about the nature of cancer cells. With the Microgravity on Human Thyroid Carcinoma Cells (Cellbox-Thyroid) study, recently...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related